Income statement
USD
Annual
| Metric | 2023 | 2002 | 2001 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | -4K | -41K | -42K |
| EBITDA | -4K | -41K | -42K |
| Net Income | -4K | -41K | -42K |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0002
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stem Cell Authority, Ltd. (SCAL) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 5.3%. Stock Foundry combines SCAL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCAL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCAL Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCAL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$42.2K
-2.2% YoY
Free Cash Flow
-$38.2K
+5.2% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2002 | 2001 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | -4K | -41K | -42K |
| EBITDA | -4K | -41K | -42K |
| Net Income | -4K | -41K | -42K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2002 | 2001 |
|---|---|---|
| Cash & Equivalents | -15 | -15 |
| Total Assets | 15 | 15 |
| Total Liabilities | 81K | 39K |
| Shareholder Equity | -81K | -39K |
| Total Debt | 0 | 0 |
| Net Debt | 15 | 15 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
38K
+5.2% YoY
Capital Expenditures
0
Free Cash Flow
38K
+5.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
7.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.